Making Quality Healthcare Affordable

World TB Day - Let's Unite to End TB


Today - 24th March - is World TB Day

World TB Day - Let's Unite to End TB

Tuberculosis is a disease that continues to kill around 1.5 million people worldwide per year, with new cases of multidrug-resistant forms (MDR-TB) affecting approximately 500,000 annually. TB is now the leading infectious cause of death worldwide.

According to the World Health Organization, barely a quarter of people thought to have MDR-TB had access to treatment in 2014, with only about half of those successfully completing treatment.

While these statistics are worrying, there are positive developments: bedaquiline and delamanid are the first new anti-TB medicines to be developed in over fifty years. The addition of these new products to existing therapies offers hope for TB patients suffering from resistant forms of the disease.

As exclusive procurement agent for the GDF of the Stop TB Partnership, IDA Foundation was able to contribute to these developments. In 2014 a Long-Term Agreement (LTA) was concluded with Janssen Pharmaceutica, the maker of bedaquiline, and IDA is currently procuring bedaquiline under the USAID-Janssen Donation Programme. Last month an LTA was concluded with Otsuka Pharmaceutical, the manufacturer of delamanid.

Delamanid and bedaquiline have the potential to dramatically improve MDR-TB treatment outcomes and reduce TB mortality worldwide.

For more information, see IDA Foundation's TB product range or visit the Stop TB partnership website.